Frontiers in oncology · 2026
Case Report: Individualized circulating tumor DNA monitoring guides olaparib adjuvant therapy: an early-stage breast cancer case with somatic BRCA2 mutation.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
You Qiuting, Gong Longlong, Chen Yi, Dinglin Xiaoxiao, Cheng Ziliang, Xia Qian, Xie Jinxia, Zhao Jianli, Su Fengxi
Аннотация
BACKGROUND: Circulating tumor DNA (ctDNA) has demonstrated a strong predictive capacity for recurrence in early-stage breast cancer compared with imaging examinations. However, there remains a paucity of robust clinical evidence to guide the adjustment of adjuvant therapy based on minimal residual disease (MRD) status in early-stage breast cancer.
CASE PRESENTATION: A 69-year-old female patient with early-stage triple-negative breast cancer (TNBC) with somatic BRCA2 mutations exhibited an exceptional response to adjuvant therapy with olaparib. Personalized ctDNA monitoring, utilizing a tumor-informed approach, was employed alongside imaging examinations and tumor biomarker testing to monitor tumor recurrence. MRD positivity was detected at four months and approximately one-month post-treatment discontinuation. Resumption of olaparib therapy resulted in a negative MRD status, while imaging examinations consistently demonstrated no evidence of recurrence in the patient.
CONCLUSIONS: This report underscores the potential benefit of olaparib for early-stage TNBC patients with somatic BRCA2 mutations and the utility of serial ctDNA monitoring for tailoring individualized treatment strategies.
CASE PRESENTATION: A 69-year-old female patient with early-stage triple-negative breast cancer (TNBC) with somatic BRCA2 mutations exhibited an exceptional response to adjuvant therapy with olaparib. Personalized ctDNA monitoring, utilizing a tumor-informed approach, was employed alongside imaging examinations and tumor biomarker testing to monitor tumor recurrence. MRD positivity was detected at four months and approximately one-month post-treatment discontinuation. Resumption of olaparib therapy resulted in a negative MRD status, while imaging examinations consistently demonstrated no evidence of recurrence in the patient.
CONCLUSIONS: This report underscores the potential benefit of olaparib for early-stage TNBC patients with somatic BRCA2 mutations and the utility of serial ctDNA monitoring for tailoring individualized treatment strategies.